Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and
Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and
Explore ADA’s 2023 updates on diabetes care, focusing on non-alcoholic fatty liver disease (NAFLD) and
Unveiling the high prevalence of NAFLD and advanced fibrosis in type 2 diabetes patients –
New this week!
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease’s pathophysiology, the impact of obesity and insulin resistance,
EDITOR OF THE MONTH!
Prof. Kenneth Cusi, a leading expert in Endocrinology, currently serves as the Chief of the Division of Endocrinology at the University of Florida. Renowned for his groundbreaking work on the correlation between NAFLD and T2DM, he has published over 150 articles in leading medical journals.
Latest Research toward the treatment of NASH disease
Knowledge is crucial for healthcare professionals to manage and diagnose patients with NASH and NAFLD. Over the years, we have been increasingly communicating the results achieved by research, showcasing the latest on therapy to diagnosis and management.
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
On International NASH Day 2023, join Michael Betel of the Fatty Liver Alliance as he
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between
Discover the importance of a multistakeholder approach in NAFLD care, addressing the challenges of comorbidities,
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease
Dr. Jörn Schattenberg (Germany) analyses the latest on the assessment in cirrhosis along with his
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
- Metabolic-associated fatty liver disease is associated with colorectal adenomas in young and older Korean adults September 22, 2023
- Expanding Pharmacists' Role in the Management of Non-Alcoholic Fatty Liver Disease September 22, 2023
- Discordance diagnosis between B-mode ultrasonography and MRI proton density fat fraction for fatty liver September 21, 2023
- Development and validation of a non-invasive model for predicting significant fibrosis based on patients with nonalcoholic fatty liver disease in the United States September 21, 2023
- Correlation of Nonalcoholic Fatty Liver Disease with Dietary Folate and Serum Folate in U.S. Adults: Cross-Sectional Analyses from National Health and Nutrition Examination Survey 2009-2018 September 21, 2023
- Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort September 20, 2023
- Exposure to ambient air pollutants, serum miRNA networks, lipid metabolism, and non-alcoholic fatty liver disease in young adults September 20, 2023
- Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice September 20, 2023
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.